论文部分内容阅读
目的:探讨甲泼尼龙联合阿奇霉素治疗小儿难治性支原体肺炎(RMPP)的疗效和安全性。方法:将88例RMPP患儿随机分为对照组(给予阿奇霉素治疗)与观察组(给予甲泼尼龙联合阿奇霉素治疗),观察两组患儿的疗效和安全性。结果:观察组临床治疗总有效率为97.73%,对照组为72.73%,差异具有统计学意义(P<0.05)。两组患儿不良反应的发生率无明显差异(P>0.05)。结论:给予RMPP患儿甲泼尼龙联合阿奇霉素治疗能够显著提高临床治疗效果,值得在临床广泛应用。
Objective: To investigate the efficacy and safety of methylprednisolone and azithromycin in the treatment of refractory mycoplasma pneumonia (RMPP) in children. Methods: A total of 88 children with RMPP were randomly divided into control group (treated with azithromycin) and observation group (given methylprednisolone combined with azithromycin) to observe the curative effect and safety of the two groups of children. Results: The total effective rate of clinical observation in observation group was 97.73% and in control group was 72.73%, the difference was statistically significant (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion: The treatment of methylprednisolone combined with azithromycin in children with RMPP can significantly improve the clinical curative effect, which is worth widely used in clinic.